1. Celgene wins FDA approval for drug key to Bristol buyout — FDA approves TAVR valves for low-risk patients — Warning signs always there for the Novartis-AveXis deal — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Dealing with a potential legal issue at work?Ask an Employment Attorney -- a chance to discuss employment-related legal issues with a practicing attorney with over 20 years in employment law experience.
    Dismiss Notice

really??!!

Discussion in 'BiogenIdec' started by anonymous, May 2, 2019 at 5:02 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

  2. anonymous

    anonymous Guest

    this article represents everything that is wrong with this pompous terrible company. People getting laid off left and right, morale at an all time low, stock plunging in the toilet, and this fool is getting a 2.5 million dollar raise. The BOD is totally out of touch with reality and this is a kick in the face to every single employee.
     
  3. anonymous

    anonymous Guest


    FOOL? Don’t you mean...TOOL??
     
  4. anonymous

    anonymous Guest

    This company lost its way years ago. It is now a bottom tier company, good place to start your career, get trained, and move on to a better biotech....
     
  5. anonymous

    anonymous Guest

    This is a big topic of discussion in the Cambridge offices. Really demotivating. 2 years in a row of 2% raises in a booming economy with recent corporate tax cuts. Also at a time when the local Boston-area cost of living is going through the roof, and in R&D they set up once a year review committees for all promotions and disallowed counter-offers to talented employees who get better offers elsewhere. It was a backdoor employee cost-cutting exercise to cut down on promotions and “unscheduled” pay increases.

    And I’m not even covering all the recent Cambridge cuts and shifting of Cambridge jobs to offshore cheap labor GBS teams, NC or remote based employees.
     
  6. anonymous

    anonymous Guest

    While I agree it wasn't warranted to give that to him let's not pretend that this is a problem limited to Biogen. This is how businesses are run here. Welcome to America.
     
  7. anonymous

    anonymous Guest

    Meanwhile you have homeless employees...
     
  8. anonymous

    anonymous Guest

    Totally agree but with all the transparency over the need for belt-tightening.. did they..(BOD, MV) even consider this might not be warranted or even a good idea? As much as I dislike unions, I can plainly see how they gain support. .
     
  9. anonymous

    anonymous Guest

    People leaving left and right, field going on plans to thin the head count, positions being filled by underqualified people....leave while you can.
     
  10. anonymous

    anonymous Guest

    this company began sucking about 5 years ago, now it’s just a joke. Pray we are bought out.
     
  11. anonymous

    anonymous Guest

    Just for the record, they have lowered NC pay bands and once we max out - no raise but a one time payout. Seems like they dare trying to make king timers and experienced employees leave.

    Because we “Care deeply”
     
  12. anonymous

    anonymous Guest

    Credit Suisse has decided to start offering Biogen crisis analysis, and it’s adding an influential voice backing some major changes at the bellwether biotech.

    “Nothing will come of nothing,” its analysts headlined in their first review of the company, pointing straight at the disastrous Phase III failure of aducanumab that has severely damaged Biogen’s market valuation.

    https://endpts.com/beleaguered-biog...ics-push-for-a-transformative-approach-to-ma/
     
  13. anonymous

    anonymous Guest

     
  14. anonymous

    anonymous Guest

    BUY! Or BE BOUGHT! Only two options
     
  15. anonymous

    anonymous Guest

    No company will buy Biogen while the Tecfidera patent is up in the air. Most are not too confident that Biogen will buy another company. The leadership does not seem competent enough to do so. They won't pull the trigger outside of a few rinky-dink solo asset buys, where no sober wall street analyst projects any blockbusters (+$1B in sales). A long-wait and a lot of what-if's for drugs that will likely peak out at $400M-$700M tops sometime in the mid-2020's.

    Watch out for those who think every drug in our pipeline is a potential blockbuster. The R&D side is LOADED with those types. They're absolutely delusional.
     
  16. anonymous

    anonymous Guest

    solid analysis and I agree. Is it possible to spin off divisions?
     
  17. anonymous

    anonymous Guest

    I call it the "Emperor's new clothes syndrome". Nobody from R&D would like to challenge RDLT's belief that the tau hypothesis will work somehow.